Exjade
(Deferasirox)
(500 mg)
(28)
(Tablets)
Exjade (deferasirox) 500 mg 28 tab NOVARTIS Switzerland
Article:
In Stock
Interchangeable drugs with the same active ingredient:
Deferasirox, exjade, exjade
Indications
Treatment of chronic iron overload due to multiple blood transfusions (≥ 7 ml/kg/month of RBCs) in patients with beta-thalassemia major aged 6 years and older.
Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
- in patients with beta-thalassemia major with iron overload due to frequent blood transfusions (³ 7 ml / kg / month of erythrocyte mass) aged 2 to 5 years;
- in patients with beta-thalassemia major with iron overload due to infrequent blood transfusions (
- in patients with other anemia aged 2 years.
- Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inappropriate in patients with thalassemia syndromes not dependent on transfusions by the age of 10 years.
-
Commercial name:Exjade
-
Сhemical name:Deferasirox
-
Dosage:500 mg
-
Quantity:28
-
Release form:Tablets
Чудовий сервіс! Все вчасно та без обману! Велике спасибі!